metformin


Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.

metformin

 [met-for´min]
a hypoglycemic agent that potentiates the action of insulin; used in treatment of type 2 diabetes mellitus.

metformin

/met·for·min/ (met-for´min) an antihyperglycemic agent that potentiates the action of insulin, used in the treatment of type 2 diabetes mellitus.

metformin

(mĕt-fôr′mĭn)
n.
An oral hypoglycemic drug, C4H11N5, usually used in its hydrochloride form, that decreases glucose production by the liver and increases peripheral glucose uptake, used to treat type 2 diabetes.

metformin

[met-for′min]
a hypoglycemic agent that potentiates the action of insulin, used in treatment of type 2 diabetes mellitus.

metformin

A biguanide antihyperglycaemic and antidiabetic used for type-2 diabetes, alone or with sulfonurea. Metformin sensitises cells to insulin, decreases serum glucose and insulin, decreases insulin resistance, increases glucose utilisation, decreases triglycerides, and reduces weight; in some patients, it suppresses appetite.

Adverse effects
GI tract complaints—e.g., diarrhoea, nausea, vomiting, bloating—occur in 30%.
 
Contraindications
Metabolic acidosis, liver disease; metformin has an equal and additive effect with troglitazone, which acts by increased peripheral glucose disposal.

metformin

Glucophage® Diabetology A biguanide antihyperglycemic and antidiabetic used for type 2 DM, alone or with sulfonurea; metformin sensitizes cells to insulin, ↓ serum glucose and insulin, ↓ insulin resistance, ↑ glucose utilization, ↓ TGs, ↓ weight; in some Pts, it suppresses appetite. See Diabetes mellitus. Cf Troglitazone.

metformin

A biguanide oral HYPOGLYCAEMIC drug used in the treatment of MATURITY ONSET DIABETES. The drug may be dangerous to those with liver or kidney disease or a high alcohol intake. The drug is on the WHO official list. A brand name is Glucophage.

metformin

biguanide agent used to treat diabetes mellitus; in presence of insulin, it decreases hepatic gluconeogenesis and increases peripheral uptake of glucose (i.e. it decreases peripheral insulin resistance); it is used to treat type 2 diabetes in cases that retain some endogenous pancreatic function, obese diabetics, and those whose blood glucose levels are not adequately controlled by sulphonylureas alone; also used in conjunction with sulphonylureas or acarbose or injected insulin or a glitazone or repaglinide; also used to treat some type 1 diabetics where it is used as an adjunct to parenteral (administered) insulin; may be used to treat polycystic ovary disease (these patients typically show insulin resistance, even though not frankly diabetic)

metformin

a biguanide used in the management of diabetes in cats. It acts by inhibiting gluconeogenesis, stimulation of peripheral glycolysis and inhibiting intestinal absorption of carbohydrates.

Patient discussion about metformin

Q. does anyone have experience switching from metformin to janumet?

A. ?
Janumet is metformin... it's a generic name for it. metformin is a substance name and there's all kind of drug companies that manufacture it (all in different names and little formula differences).

Q. I'm a diabetic and have been on metformin for aprox. 4 yrs. The Dr. upped my dose and my sugar levels went way up. I stopped taking it and for the last two days sugar levels have stayed between 115 and 135. Whereas, with the higher dose of metformin. It reached 269. Diet is the same. What is going on. And do I trust my Dr. evaluation.

A. I doubt the cause of the sugar rise has any relation to the Metformin increased dosage. It could be your body has stopped reacting to Metformin- that happens to almsot all patients with diabetes after a while, and a combination treatment with another drug or a change in drugs is performed. You should remain on the new dosage for another week or two, and keep track of your sugar level meanwhile, and if things don't improve then you should see your doctor again so that he/she will make a new evaluation.

More discussions about metformin
References in periodicals archive ?
Clinical research demonstrated that sustained virological response was improved by adding metformin to the standard of care for patients with chronic hepatitis C genotype 1 and IR.
The Diabetes Prevention Program (DPP) study showed that long-term metformin use in individuals with impaired glucose tolerance was associated with an increased risk of anemia, and this was independent of vitamin [B.
KEYWORDS: Gestational diabetes, Insulin, Fetal outcomes, Maternal outcomes, Metformin.
12] deficiency, however, as people who developed anemia while taking metformin were more likely to develop microcytic (12% vs.
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).
In this article, we'll review data that persuaded the FDA to allow metformin to be studied in humans as the first anti-aging drug.
This analysis involved nondiabetic controls (n = 554), metformin untreated T2DM (n = 106), metformin treated T2DM (n = 93), and type 1 diabetes patients (n = 31).
The product is an investigational drug designed to target metformin delivery to the lower small intestine, where it is minimally absorbed, yet elicits robust glucose lowering effects.
Lower doses or shorter courses of metformin reduce fasting plasma glucose (SOR: C, RCTs with laboratory outcomes) and may reduce the risk of developing diabetes by a smaller amount (SOR: C, flawed RCT).
In basic science studies, metformin has been shown to stop mTOR, a molecular pathway present and active in this type of head and neck cancer, and pretreatment with metformin resulted in a decrease in the occurrence of oral cavity tumors in animal models.
The incidence of preeclampsia was also lower with metformin than with placebo (3.